EQS-Adhoc: Lonza .
EQS-Adhoc: Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin
vom 23.07.2021, 07:01 Uhr
Bild: pixabay.com
EQS Group-Ad-hoc: Lonza Group AG / Key word(s): Half Year Results
Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin
23-Jul-2021 / 07:01 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Ad Hoc Release Pursuant to Art. 53 Listing Rules
In H1 2021, Lonza continued its strong performance with 14.7%
1 sales growth and 33.3% CORE EBITDA margin, despite headwinds arising from COVID-19
Continued focus on growth CAPEX investments, supported by strong business pipeline
EQS-Adhoc: Lonza Group AG: Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin
Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin
23-Jul-2021 / 07:01 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Ad Hoc Release Pursuant to Art. 53 Listing Rules
In H1 2021, Lonza continued its strong performance with 14.7%
1 sales growth and 33.3% CORE EBITDA margin, despite headwinds arising from COVID-19
Continued focus on growth CAPEX investments, supported by strong business pipeline
Expanded collaborations to support COVID-19 programs including Moderna
EQS-Adhoc: Lonza Group AG: Lonza Extends Collaboration with Major Biopharmaceutical Partner for Large-Scale Monoclonal Antibody Commercial Supply
Lonza Extends Collaboration with Major Biopharmaceutical Partner for Large-Scale Monoclonal Antibody Commercial Supply
16-Jul-2021 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Long-term collaboration for commercial supply of monoclonal antibodies will complete the integrated supply chain for the manufacture of an antibody-drug conjugate (ADC) for use against hard-to-treat cancers
The deal enables the customer to access commercial-scale production of all elements of its ADC at one site, ensuring security of supply and delivering significant economies of scale. It demonstrates the value of Lonza s Ibex
EQS-Adhoc: Lonza Extends Collaboration with Major Biopharmaceutical Partner for Large-Scale Monoclonal Antibody Commercial Supply
vom 16.07.2021, 07:00 Uhr
Bild: pixabay.com
Lonza Extends Collaboration with Major Biopharmaceutical Partner for Large-Scale Monoclonal Antibody Commercial Supply
16-Jul-2021 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Long-term collaboration for commercial supply of monoclonal antibodies will complete the integrated supply chain for the manufacture of an antibody-drug conjugate (ADC) for use against hard-to-treat cancers
The deal enables the customer to access commercial-scale production of all elements of its ADC at one site, ensuring security of supply and delivering significant economies of scale. It demonstrates the value of Lonza s Ibex
Lonza Group AG / Key word(s): Agreement/Development of Sales
16-Jul-2021 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Long-term collaboration for commercial supply of monoclonal antibodies will complete the integrated supply chain for the manufacture of an antibody-drug conjugate (ADC) for use against hard-to-treat cancers
The deal enables the customer to access commercial-scale production of all elements of its ADC at one site, ensuring security of supply and delivering significant economies of scale. It demonstrates the value of Lonza s Ibex
(R) Solutions, providing customers with fast, flexible and tailor-made solutions